Lava Therapeutics N.V. (LVTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Sales | 11,982 | 6,769 | 19,391 | 5,350 | 3,500 |
| Cost of Goods | N/A | 3,482 | N/A | N/A | N/A |
| Gross Profit | 11,982 | 3,287 | 19,391 | 5,350 | 3,500 |
| Operating Expenses | 41,675 | 47,163 | 54,229 | 48,963 | 18,420 |
| Operating Income | -29,693 | -43,394 | -34,838 | -43,613 | -14,920 |
| Interest Expense | 515 | 470 | 0 | 0 | 342 |
| Other Income | 5,724 | 2,250 | 3,180 | 1,415 | -201 |
| Pre-tax Income | -24,484 | -41,614 | -31,658 | -42,198 | -15,463 |
| Income Tax | 630 | 257 | 249 | 157 | 43 |
| Net Income Continuous | -25,114 | -41,871 | -31,907 | -42,355 | -15,506 |
| Net Income | $-25,114 | $-41,871 | $-31,907 | $-42,355 | $-15,506 |
| EPS Basic Total Ops | -0.94 | -1.57 | -1.23 | -2.14 | -38.85 |
| EPS Basic Continuous Ops | -0.94 | -1.57 | -1.23 | -2.14 | -38.86 |
| EPS Diluted Total Ops | -0.94 | -1.57 | -1.23 | -2.14 | -38.85 |
| EPS Diluted Continuous Ops | -0.94 | -1.57 | -1.23 | -2.14 | -38.86 |
| EPS Diluted Before Non-Recurring Items | -0.94 | -1.57 | -1.23 | -2.30 | N/A |
| EBITDA(a) | $-31,862 | $-44,682 | $-34,191 | $-42,609 | $-14,456 |